Literature DB >> 25844350

Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Sylvia Villeneuve1, William J Jagust1.   

Abstract

Vascular risk factors (e.g. hypertension, dyslipidemia and diabetes) are well known risk factors for Alzheimer' disease. These vascular risk factors lead to vascular brain injuries, which also increase the likelihood of dementia. The advent of amyloid PET imaging has helped establish that vascular risk factors also lead to Alzheimer's disease via pathways that are independent from vascular brain injuries, at least, when vascular brain injuries are measured as white matter lesions and infarcts. While vascular brain injuries (white matter lesions and infarcts) do not seem to influence amyloid pathology, some evidence from amyloid imaging suggests that increased vascular risk is related to increased amyloid burden. Furthermore, while vascular brain injuries and amyloid have an additive and independent impact on brain integrity, vascular risk factors might potentiate the impact of amyloid on cortical thickness on brain regions vulnerable to Alzheimer's disease. New research should further explore and confirm, or refute, possible interactions between amyloid and vascular risk factors on brain integrity and cognition. Neuroimaging tools used to assess vascular brain integrity should also be expanded. Measuring cortical blood flow or damage to the capillary system might, for instance, give insight about how vascular risk factors can be associated to amyloid burden and impact. These findings also stress the need for monitoring vascular risk factors in midlife as a strategy for Alzheimer's disease prevention.

Entities:  

Keywords:  Alzheimer’ disease; amyloid; treatment; vascular brain injuries; vascular risk factors

Year:  2015        PMID: 25844350      PMCID: PMC4381867          DOI: 10.14283/jpad.2015.47

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  60 in total

1.  Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

2.  Multiple Brain Markers are Linked to Age-Related Variation in Cognition.

Authors:  Trey Hedden; Aaron P Schultz; Anna Rieckmann; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Randy L Buckner
Journal:  Cereb Cortex       Date:  2014-10-14       Impact factor: 5.357

3.  Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients.

Authors:  Byoung Seok Ye; Sang Won Seo; Geon Ha Kim; Young Noh; Hanna Cho; Cindy W Yoon; Hee Jin Kim; Juhee Chin; Seun Jeon; Jong Min Lee; Joon-Kyung Seong; Jae Seung Kim; Jae-Hong Lee; Yearn Seong Choe; Kyung Han Lee; Young H Sohn; Michael Ewers; Michael Weiner; Duk L Na
Journal:  Alzheimers Dement       Date:  2014-07-19       Impact factor: 21.566

4.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

5.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

Authors:  J A Schneider; R S Wilson; J L Bienias; D A Evans; D A Bennett
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

Review 7.  Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease.

Authors:  Lidia Glodzik; Catherine Randall; Henry Rusinek; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 9.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  12 in total

1.  Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters.

Authors:  Catherine C Price; Jared J Tanner; Ilona M Schmalfuss; Babette Brumback; Kenneth M Heilman; David J Libon
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau.

Authors:  Jennifer S Rabin; Hyun-Sik Yang; Aaron P Schultz; Bernard J Hanseeuw; Trey Hedden; Anand Viswanathan; Jennifer R Gatchel; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Vaishnavi Rao; Rachel F Buckley; Wai-Ying Wendy Yau; Dylan R Kirn; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  Ann Neurol       Date:  2019-01-07       Impact factor: 10.422

3.  APOEε4 Genotype and Hypertension Modify 8-year Cortical Thinning: Five Occasion Evidence from the Seattle Longitudinal Study.

Authors:  Philippe Rast; Kristen M Kennedy; Karen M Rodrigue; Paul R A W Robinson; Alden L Gross; Donald G McLaren; Tom Grabowski; K Warner Schaie; Sherry L Willis
Journal:  Cereb Cortex       Date:  2018-06-01       Impact factor: 5.357

4.  Editorial: Preventive Trials for Alzheimer's Diseases: The Multi-domain and the Targeted Therapies Approaches Will Have to Be Associated.

Authors:  J Lin; B Dong; B Vellas
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

5.  Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy.

Authors:  Jennifer S Rabin; Jeremy Pruzin; Matthew Scott; Hyun-Sik Yang; Olivia Hampton; Stephanie Hsieh; Aaron P Schultz; Rachel F Buckley; Trey Hedden; Dorene Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  Neurology       Date:  2022-04-26       Impact factor: 11.800

6.  Cardiovascular Risk Factors Across the Life Course and Cognitive Decline: A Pooled Cohort Study.

Authors:  Kristine Yaffe; Eric Vittinghoff; Tina Hoang; Karen Matthews; Sherita H Golden; Adina Zeki Al Hazzouri
Journal:  Neurology       Date:  2021-03-17       Impact factor: 9.910

7.  Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.

Authors:  Angela Tam; Christian Dansereau; AmanPreet Badhwar; Pierre Orban; Sylvie Belleville; Howard Chertkow; Alain Dagher; Alexandru Hanganu; Oury Monchi; Pedro Rosa-Neto; Amir Shmuel; Seqian Wang; John Breitner; Pierre Bellec
Journal:  Front Aging Neurosci       Date:  2015-12-24       Impact factor: 5.750

Review 8.  Is late-onset Alzheimer's disease really a disease of midlife?

Authors:  Karen Ritchie; Craig W Ritchie; Kristine Yaffe; Ingmar Skoog; Nikolaos Scarmeas
Journal:  Alzheimers Dement (N Y)       Date:  2015-07-26

9.  The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease.

Authors:  Julia Kim; Tom A Schweizer; Corinne E Fischer; David G Munoz
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Authors:  S Gauthier; H Zhang; K P Ng; T A Pascoal; P Rosa-Neto
Journal:  Transl Neurodegener       Date:  2018-05-31       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.